Mode
Text Size
Log in / Sign up
N/A N=63 Randomized Single-blind Treatment

Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa

Retinitis Pigmentosa

Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcome: Primary: Visual Field, III4e — 4835.29; 4988.43; 6234.59; 4488.39 deg2

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Transcorneal electrostimulation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Okuvision GmbH
Primary completion
Aug 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Field, III4e
4835.29; 4988.43; 6234.59; 4488.39; 4962.76; 5878.75
PRIMARY
Visual Field, V4e
7135.77; 7599.65; 8303.59; 6730.20; 7641.55; 8112.18
SECONDARY
ERG B-wave
SECONDARY
ERG A-wave
SECONDARY
BCVA
SECONDARY
VFQ-25
SECONDARY
Dark Adaptation

Summary

The purpose of this study is to determine the long-term effects of transcorneal electrostimulation (TcES) in patients with retinitis pigmentosa (RP). In a prior study (NCT00804102) the results of short-term stimulation showed a positive effect on the visual field and other parameters. In this study, the patients will be stimulated with either 0%, 150% or 200% of the individually determined phosphene threshold.

Eligibility Criteria

Inclusion Criteria

  • Adult subject with RP (rod-cone dystrophy)
  • BCVA 0.02 to 0.9
  • Reliable visual field measurements
  • Reliable ERG measurements
  • Skillful enough to use the device at home
  • Able to give consent and take part during the whole study

Exclusion Criteria

  • Diabetic retinopathy
  • Neovascularisation of any origin
  • After arterial or venous occlusion
  • After retinal detachment
  • Silicone oil tamponade
  • Dry or exudative age-related macular degeneration
  • Macular edema
  • All forms of glaucoma
  • Any form of corneal degeneration that reduces visual acuity
  • Systemic diseases that are difficult to control or manage, that could endanger the normal study schedule
  • Patients in a permanently poor general condition, which could hinder the regular attendance at control examinations in the clinic
  • Forms of mental illness related to the bipolar affective and schizoid-affective disorders, and all forms of dementia
  • Simultaneous participation in another interventional study or history of interventions whose effect may still persist
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01837901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search